Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 3/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20241281 | 0.90 | GABRA1 (0.37) | GABRA1PKM | |
| SCHEMBL29421383 | 0.80 | BTK (0.48) | GABRA1 | |
| SCHEMBL21403868 | 0.80 | GABRA1 (0.36) | GABRA1 | |
| SCHEMBL14568952 | 0.74 | GAA (0.38) | — | |
| SCHEMBL22729494 | 0.73 | EPHX2 (0.49) | — | |
| SCHEMBL9278682 | 0.73 | POLB (0.33) | PKM | |
| SCHEMBL8608407 | 0.73 | POLB (0.33) | PKM | |
| SCHEMBL9278676 | 0.73 | POLB (0.33) | PKM | |
| SCHEMBL9791763 | 0.73 | POLB (0.33) | PKM | |
| SCHEMBL22729536 | 0.72 | EPHX2 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220411415-A1 | ISOXAZOLYL ETHER DERIVATIVES AS GABA A ALPHA5 PAM | HOFFMANN-LA ROCHE INC. (US) | 2022-12-29 | — | — | US | disclosed |
| EP-3551627-B1 | NEW ISOXAZOLYL ETHER DERIVATIVES AS GABA A ALPHA5 PAM | HOFFMANN LA ROCHE (CH) | 2022-02-16 | — | — | EP | disclosed |
| US-11091471-B2 | Isoxazolyl ether derivatives as GABAA α5 PAM | HOFFMANN-LA ROCHE INC. (US) | 2021-08-17 | — | — | US | disclosed |
| US-20190300516-A1 | ISOXAZOLYL ETHER DERIVATIVES AS GABA A ALPHA5 PAM | HOFFMANN-LA ROCHE INC. (US) | 2019-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190300516-A1 | ISOXAZOLYL ETHER DERIVATIVES AS GABA A ALPHA5 PAM | GABRA5, GABRB1, GABRA1 | GABRA1 3/4885PKM 943/4885HCRTR2 380/4885 |
| US-20220411415-A1 | ISOXAZOLYL ETHER DERIVATIVES AS GABA A ALPHA5 PAM | GABRA5, GABRB1, GABRA1 | GABRA1 3/4885PKM 943/4885HCRTR2 380/4885 |
| US-11091471-B2 | Isoxazolyl ether derivatives as GABAA α5 PAM | GABRA5, GABRA1, GABRA3 | GABRA1 2/4885PKM 1098/4885HCRTR2 532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.